Lupin Limited
NSE: LUPININE326A01037·HealthcareMidcap 150·Mcap ₹96,026 Cr·Listed 2001
₹2,092.00▼ ₹8.70  (−0.41%)
52W: ₹1,900 – ₹2,530 · Vol: 4.3L shares · Close 25 Sept
Set Alert

Quarterly results

consolidated · as filed with NSE · Q1 FY27 back to Q4 FY18
₹ croreQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24Q4 FY23Q3 FY23Q2 FY23Q4 FY22Q3 FY22Q2 FY22Q1 FY22Q4 FY21Q3 FY21Q2 FY21Q1 FY21Q4 FY20Q3 FY20Q2 FY20Q1 FY20Q4 FY19Q3 FY19Q2 FY19Q1 FY19Q4 FY18
Revenue from operations8,2777,4757,1687,0486,2685,6675,7685,6735,6004,9615,1975,0394,8144,4304,3224,1463,8834,1614,0914,2703,7834,0173,8353,5283,8463,7694,3604,4184,3264,5053,9513,8563,978
Other income13014111590795753.742.367.829.329.440.422.837.31814.915.734.172.827.858.221.22543.320993.613372.216743.4231184200
Total expenses6,3905,5565,3345,1314,9324,8284,7504,6604,6754,4924,4914,4494,2784,2094,0943,9513,9844,0286,3693,5483,3233,5143,5003,2993,6423,6824,0373,9613,9004,1123,7413,6573,656
EBITDA2,4502,4862,2622,3411,7271,3211,3561,3401,2419971,038918856578533453268370−1,324965708779581488525429731860792753550527653
EBITDA margin29.6%33.3%31.6%33.2%27.6%23.3%23.5%23.6%22.2%20.1%20.0%18.2%17.8%13.0%12.3%10.9%6.9%8.9%-32.4%22.6%18.7%19.4%15.2%13.8%13.7%11.4%16.8%19.5%18.3%16.7%13.9%13.7%16.4%
Finance costs11012011510891.889.166.970.96871.37480.685.792.684.154.941.533.434.433.531.830.933.644.310788.686.585.685.579.873.868.758.5
Depreciation453447313317299393271257248457257248235264220203327203919209216244213215214253321317281280265259273
Profit before tax2,0171,9281,5222,0071,4168961,0711,055993498736630559259246210−85.2167−2,205750518525360272495−108−90.153059694.2441383−942
Tax60045934252219411321219518712911713410516.188.575.1427−382−1102025483.514716410576734.3228300248173181−163
Net profit1,4171,4691,1811,4851,221782859859806368619495453242158134−512549−2,095548464441214109391−840−123303296−152268203−778
Net margin17.1%19.6%16.5%21.1%19.5%13.8%14.9%15.2%14.4%7.4%11.9%9.8%9.4%5.5%3.6%3.2%-13.2%13.2%-51.2%12.8%12.3%11.0%5.6%3.1%10.2%-22.3%-2.8%6.9%6.9%-3.4%6.8%5.3%-19.5%
EPS (₹)30.9531.9625.7432.3626.7016.9318.7518.7017.587.8913.4710.769.945.193.382.85-11.4012.01-46.2211.9610.249.744.712.408.64-19.30-2.816.706.35-3.365.884.487.93
Net profit YoY+16.0%+87.7%+37.5%+72.8%+51.6%+112.5%+38.8%+73.5%+77.7%+51.9%+292.5%+268.3%–+147.4%−71.3%+106.4%−210.2%+24.4%−1081.2%+404.3%+18.7%+152.5%+273.0%−64.1%+32.0%−451.6%−146.0%+49.1%+138.1%––––

Annual results

financial years ending March · from the fourth-quarter filings
₹ croreFY26FY25FY24FY23FY22FY21FY20FY19FY18
Revenue from operations27,95822,70820,01116,64216,40515,16315,37516,36915,560
Other income42419612073.4142136484713395
Total expenses20,95218,88917,70915,99917,92013,62414,35315,22913,947
EBITDA8,8165,2833,8111,7982872,5672,3552,5332,903
EBITDA margin31.5%23.3%19.0%10.8%1.8%16.9%15.3%15.5%18.7%
Finance costs434295312274143141363308204
Depreciation1,3761,1691,1978811,6598879701,0851,086
Profit before tax6,8734,0152,422716−1,3731,6757531,517543
Tax1,5177094872691374491,157902288
Net profit5,3553,3061,936448−1,5091,228−270615258
Net margin19.2%14.6%9.7%2.7%-9.2%8.1%-1.8%3.8%1.7%
EPS (₹)116.7571.9542.059.46-33.6527.09-8.8320.9330.83
Net profit YoY+62.0%+70.8%+332.3%+129.7%−222.9%+555.2%−143.8%+138.2%–
EPS is as filed for each period and is not restated for later bonus issues or splits.

Cash flow

annual · ₹ crore
₹ croreFY26FY25FY24FY23FY22
Operating cash flow7,5464303,4901,9341,082
Investing cash flow−4,076−1,602−1,554−1,324577
Financing cash flow−8461,732−2,184−337−1,572
Capital expenditure2,0551,6829291,500905
Free cash flow (CFO − capex)5,491−1,2522,562435177

Net profit trend

annual, ₹ crore
FY21
₹1,228
FY22
₹−1,509−223%
FY23
₹448+130%
FY24
₹1,936+332%
FY25
₹3,306+71%
FY26
₹5,355+62%

Result filings

as filed with NSE · PDF and XBRL
PeriodBasisFiledDocuments
Q1 FY27Consolidated6 Aug 2026PDF on NSE XBRL
Q1 FY27Standalone6 Aug 2026PDF on NSE XBRL
Q4 FY26Consolidated · audited7 May 2026PDF on NSE XBRL
Q4 FY26Standalone · audited8 May 2026PDF on NSE XBRL
Q3 FY26Consolidated12 Feb 2026PDF on NSE XBRL
Q3 FY26Standalone12 Feb 2026PDF on NSE XBRL
Q2 FY26Consolidated6 Nov 2025PDF on NSE XBRL
Q2 FY26Standalone6 Nov 2025PDF on NSE XBRL
Q1 FY26Consolidated5 Aug 2025PDF on NSE XBRL
Q1 FY26Standalone5 Aug 2025PDF on NSE XBRL

Annual reports

NSE archive
Key ratios
P/E (TTM)5Y avg 38.1×17.2×
P/B5Y avg 4.40×4.26×
ROEFY26, on average equity27.0%
Net margin19.2%
Debt / equity0.26×
Revenue CAGR (3Y)18.9%
Profit CAGR (3Y)128.7%
EPS (TTM)₹121.41
Market cap₹95,646 Cr
Computed from the filings and the last close. Market cap uses the latest share count from the balance sheet.
P/B vs history
4.26×
vs 8-point avg 4.40× (−3%)
2.38× low4.40× avg6.40× high
History points are balance-sheet dates (2022 → 2026), priced at the adjusted close on each date.
Balance sheet 31 Mar 2026
Total assets₹38,365 Cr+31%
Net worth₹22,448 Cr+30%
Total borrowings₹5,910 Cr+16%
Cash & bank balances₹4,168 Cr+170%
Investments₹3,641 Cr+225%
Inventories₹6,083 Cr+11%
Trade receivables₹6,604 Cr+20%
Trade payables₹4,173 Cr+41%
Change vs the same date a year earlier.
Revenue mix FY26
Pharmaceuticals99.5%result ₹7,050 Cr
Others0.5%result ₹−178 Cr
Segment revenue as reported, before inter-segment eliminations.
Shareholding 30 Jun 2026
%Jun 26Mar 26Dec 25Sept 25Jun 25Mar 25Dec 24Sept 24Jun 24Mar 24Dec 23Sept 23
Promoter46.8546.8646.8946.9046.9046.9246.9546.9646.9847.0147.0447.06
FII22.4221.7121.4920.4921.2521.4622.0421.5019.3218.2816.1114.99
DII24.6525.3225.5826.5525.5625.4124.7425.0926.7827.7629.7329.42
of which MF14.8416.9318.0120.5719.35–––––––
Retail5.065.065.105.125.235.105.175.295.655.705.876.24
Other public1.021.050.940.941.061.111.101.161.271.251.252.29
3,00,283 shareholders · NSE shareholding pattern filings.